Erectile Dysfunction (ED) Drugs Market Outlook 2028

  • The global erectile dysfunction (ED) drugs market was valued at US$ 3.4 Bn in 2020
  • It is estimated to incur value growth at CAGR of -3.1% from 2021 to 2028
  • The global erectile dysfunction (ED) drugs market is expected to reach the value of US$ 2.5 Bn by the end of 2028

Erectile Dysfunction (ED) Drugs Market: Overview

  • According to Transparency Market Research’s latest report on the global erectile dysfunction (ED) drugs market for the historical period 2017–2019 and forecast period 2021–2028, some factors that drive the erectile dysfunction (ED) drugs market include the adoption of sedentary lifestyle and its associated stress, rising geriatric population, and comorbidity between erectile dysfunction and heart disease and diabetes

To know the scope of our report Get a Sample on Erectile Dysfunction (ED) Drugs Market

Increase in Awareness and Patient Education: Key Driver

  • Educating patients on the appropriate use of erectile dysfunction drugs can be effective through initial education and focusing on the method of administration of drugs. For instance, sildenafil and vardenafil should be taken an hour before intercourse, and food and alcohol intake should be avoided, thereby maintaining the speed and extent of drug absorption. Both the drugs are active for four to six hours. Tadalafil has an advantage of long duration of action i.e., for up to 36 hours. The absorption of tadalafil is unaffected by food and alcohol and the intake of tadalafil is advised several hours before sexual activity. Moreover, adequate sexual stimulation, ideally with a partner, is required.
  • Promotional and awareness campaigns for ED drugs should be extensively conducted to help minimize the stigma of impotence by bringing it out onto open discussion forums
  • Companies are working on educating the general population and people at risk, and advocating lifestyle changes
  • Pharmacists assess the needs of patients and identify drug problems to manage medication therapy

Get a glimpse of the in-depth analysis through our Report Brochure

Narrowing of Insurance Coverage for Erectile Dysfunction Treatment

  • Development of pharmaceutical and branded drugs incurs large investments and longer duration of time in R&D activities and making them available to the patients for the treatment
  • Modifications in the healthcare insurance coverage can significantly affect the drug market. If an insurance program changes its policies and removes coverage for a certain treatment, sales of related drugs are likely to decrease. In general, insurance programs are more likely to cover essential expenses, such as heart disease medication, and are less likely to cover nonessential expenses, such as cosmetic surgery. The type of treatment prescribed for erectile dysfunction decides the possibility of insurance coverage. A person with a documented medical condition responsible for the cause of erectile dysfunction could incur insurance benefits. However, sex therapies and medications that have not been approved by the FDA have not been covered under insurance.
  • Due to low dynamic nature, the trend of switching to new drugs or automatic substitution is not prevalent in the erectile dysfunction drugs market, thereby creating further hurdles for players willing to enter the market

Expanding operations in future? To get the perfect launch ask for a custom report

Erectile Dysfunction (ED) Drugs Market: Competition Landscape

  • This report profiles major players in the global erectile dysfunction (ED) drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global erectile dysfunction (ED) drugs market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global erectile dysfunction (ED) drugs market are
    • Pfizer, Inc.
    • Dong-A ST Co., Ltd.
    • Eli Lilly and Company
    • Bayer AG
    • Vivus, Inc.
    • Teva Pharmaceutical Industries Ltd.
  • Manufacturers are launching new products in the international market to tap the unmet needs of erectile dysfunction
  • Other prominent players operating in the global market include SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Futura Medical plc.

Erectile Dysfunction (ED) Drugs Market: Key Developments

  • Key players in the global erectile dysfunction (ED) drugs market are expanding their market position by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market positions across the world. A few expansion strategies adopted by players operating in the global erectile dysfunction (ED) drugs market are:
    • In December 2020, Glenmark Pharma received the final approval from the U.S. health regulator for Tadalafil tablets, which are used to treat erectile dysfunction and enlarged prostate
    • In June 2020, Launch Medical and GAINSWave announced the resolution of their lawsuit and started working together to market their revolutionary home-use acoustic wave device called The Phoenix for the treatment of erectile dysfunction
  • The report on the global erectile dysfunction (ED) drugs market discusses individual strategies, followed by company profiles of manufacturers of medical device technology products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global erectile dysfunction (ED) drugs market.

Erectile Dysfunction (ED) Drugs Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 3.4 Bn

Market Forecast Value in 2028

US$ 2.5 Bn

Growth Rate (CAGR)

(3.1)%

Forecast Period

2021–2028

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market Player - Competition Matrix (by tier and size of companies)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug
    • Viagra
    • Cialis
    • Staxyn/Levitra
    • Stendra/Spedra
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer, Inc.
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Bayer AG
  • Vivus, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • SK Chemicals
  • Meda Pharmaceuticals, Inc.
  • Cristalia Produtos Quimicos Farmaceuticos Ltda. Apricus Biosciences, Inc.
  • Futura Medical plc
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Note: Brackets for CAGR represent negative value.

Erectile Dysfunction (ED) Drugs Market – Scope of Report

TMR’s report on the global erectile dysfunction (ED) drugs market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global erectile dysfunction (ED) drugs market for the period 2020–2028, considering 2020 as the base year and 2021 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global erectile dysfunction (ED) drugs market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global erectile dysfunction (ED) drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global erectile dysfunction (ED) drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global erectile dysfunction (ED) drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global erectile dysfunction (ED) drugs market.

The report delves into the competition landscape of the global erectile dysfunction (ED) drugs market. Key players operating in the global erectile dysfunction (ED) drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global erectile dysfunction (ED) drugs market that have been profiled in this report.

Key Questions Answered in Erectile Dysfunction (ED) Drugs Market Report

  • What is the scope of growth of product companies in the global erectile dysfunction (ED) drugs market?
  • What will be the Y-o-Y growth of the global erectile dysfunction (ED) drugs market between 2020 and 2028?
  • What is the influence of changing trends in technologies on the global erectile dysfunction (ED) drugs market?
  • Will North America be the most profitable market for medical device technology providers?
  • Which factors are anticipated to hamper the growth of the global erectile dysfunction (ED) drugs market during the forecast period?
  • Which are the leading companies in the global erectile dysfunction (ED) drugs market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global erectile dysfunction (ED) drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global erectile dysfunction (ED) drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the erectile dysfunction (ED) drugs market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the erectile dysfunction (ED) drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global erectile dysfunction (ED) drugs market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global erectile dysfunction (ED) drugs market more reliably and accurately.

Erectile Dysfunction (ED) Drugs Market - Segmentation

Drug
  • Viagra
  • Cialis
  • Staxyn/Levitra
  • Stendra/Spedra
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

1. Preface

    1.1. Market Segmentation

    1.2. Key Research Objectives

    1.3. Research Highlights

2. Assumptions and Research Methodology

    2.1. Secondary Research Methodology

    2.2. Primary Research Methodology

    2.3. Analysis Research Methodology

3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

5. Market Outlook

    5.1. Market Dynamics

        5.1.1. Drivers

        5.1.2. Restraints

        5.1.3. Opportunity

        5.1.4. Opportunity Analysis

        5.1.5. Trends

    5.2. Global Erectile Dysfunction Market Analysis and Forecast, 2018–2028

    5.3. Porter’s Five Forces Analysis

    5.4. Erectile Dysfunction Drugs Market Value Chain Analysis

    5.5. Pipeline Analysis

        5.5.1. Discovery

        5.5.2. Preclinical

        5.5.3. IND (Investigational New Drug)

        5.5.4. Phase I

        5.5.5. Phase I/II

        5.5.6. Phase II

        5.5.7. Phase III

        5.5.8. Pre-registration

    5.6. Global Erectile Dysfunction (ED) Drug Market Outlook

6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Drug

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug, 2018–2028

        6.3.1. Viagra

        6.3.2. Cialis

        6.3.3. Staxyn/Levitra

        6.3.4. Stendra/Spedra

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Drug

7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Distribution Channel, 2018–2028

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Drug, 2018–2028

        9.2.1. Viagra

        9.2.2. Cialis

        9.2.3. Staxyn/Levitra

        9.2.4. Stendra/Spedra

        9.2.5. Others

    9.3. Market Value Forecast, by Distribution Channel, 2018–2028

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Value Forecast, by Country, 2018–2028

        9.4.1. U.S.

        9.4.2. Canada

10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug, 2018–2028

        10.2.1. Viagra

        10.2.2. Cialis

        10.2.3. Staxyn/Levitra

        10.2.4. Stendra/Spedra

        10.2.5. Others

    10.3. Market Value Forecast, by Distribution Channel, 2018–2028

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Market Value Forecast, by Country/Sub-region, 2018–2028

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug, 2018–2028

        11.2.1. Viagra

        11.2.2. Cialis

        11.2.3. Staxyn/Levitra

        11.2.4. Stendra/Spedra

        11.2.5. Others

    11.3. Market Value Forecast, by Distribution Channel, 2018–2028

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Market Value Forecast, by Country/Sub-region, 2018–2028

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug, 2018–2028

        12.2.1. Viagra

        12.2.2. Cialis

        12.2.3. Staxyn/Levitra

        12.2.4. Stendra/Spedra

        12.2.5. Others

    12.3. Market Value Forecast, by Distribution Channel, 2018–2028

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Market Value Forecast, by Country/Sub-region, 2018–2028

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug, 2018–2028

        13.2.1. Viagra

        13.2.2. Cialis

        13.2.3. Staxyn/Levitra

        13.2.4. Stendra/Spedra

        13.2.5. Others

    13.3. Market Value Forecast, by Distribution Channel, 2018–2028

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Market Value Forecast, by Country/Sub-region, 2018–2028

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2020

    14.3. Competitive Business Strategies

    14.4. Company Profiles

        14.4.1. Pfizer, Inc.

            14.4.1.1. Company Overview (HQ, Business Segments, Employee)

            14.4.1.2. Product Portfolio

            14.4.1.3. SWOT Analysis

            14.4.1.4. Strategic Overview

        14.4.2. Dong-A ST Co., Ltd.

            14.4.2.1. Company Overview (HQ, Business Segments, Employee)

            14.4.2.2. Product Portfolio

            14.4.2.3. SWOT Analysis

            14.4.2.4. Strategic Overview

        14.4.3. Eli Lilly and Company

            14.4.3.1. Company Overview (HQ, Business Segments, Employee)

            14.4.3.2. Product Portfolio

            14.4.3.3. SWOT Analysis

            14.4.3.4. Strategic Overview

        14.4.4. Bayer AG

            14.4.4.1. Company Overview (HQ, Business Segments, Employee)

            14.4.4.2. Product Portfolio

            14.4.4.3. SWOT Analysis

            14.4.4.4. Strategic Overview

        14.4.5. VIVUS, INC.

            14.4.5.1. Company Overview (HQ, Business Segments, Employee)

            14.4.5.2. Product Portfolio

            14.4.5.3. SWOT Analysis

            14.4.5.4. Strategic Overview

        14.4.6. SK chemicals

            14.4.6.1. Company Overview (HQ, Business Segments, Employee)

            14.4.6.2. Product Portfolio

            14.4.6.3. SWOT Analysis

            14.4.6.4. Strategic Overview

        14.4.7. Meda Pharmaceuticals, Inc.

            14.4.7.1. Company Overview (HQ, Business Segments, Employee)

            14.4.7.2. Product Portfolio

            14.4.7.3. SWOT Analysis

            14.4.7.4. Strategic Overview

        14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.

            14.4.8.1. Company Overview (HQ, Business Segments, Employee)

            14.4.8.2. Product Portfolio

            14.4.8.3. SWOT Analysis

            14.4.8.4. Strategic Overview

        14.4.9. Apricus Biosciences, Inc.

            14.4.9.1. Company Overview (HQ, Business Segments, Employee)

            14.4.9.2. Product Portfolio

            14.4.9.3. SWOT Analysis

            14.4.9.4. Strategic Overview

        14.4.10. Teva Pharmaceutical Industries Ltd.

            14.4.10.1. Company Overview (HQ, Business Segments, Employee)

            14.4.10.2. Product Portfolio

            14.4.10.3. SWOT Analysis

            14.4.10.4. Strategic Overview

List of Tables

Table 01: Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028

Table 02: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 03: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2018–2028

Table 04: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2018–2028

Table 05: North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028

Table 06: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 07: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table 08: Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028

Table 09: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 10: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table 11: Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028

Table 12: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 13: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table 14: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028

Table 15: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 16: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2028

Table 17: Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018–2028

Table 18: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2028

Table 19: Pfizer, Inc. Products Offered

Table 20: Pfizer, Inc. Recent Developments

Table 21: Dong-A ST Co., Ltd. Products Offered

Table 22: Dong-A ST Co., Ltd. Recent Developments

Table 23: Eli Lilly and Company Products Offered

Table 24: Eli Lilly and Company Recent Developments

Table 25: Bayer AG Products Offered

Table 26: Bayer AG Recent Developments

Table 27: VIVUS, INC. Ltd. Products Offered

Table 28: VIVUS, INC. Recent Developments

Table 29: SK chemicals Products Offered

Table 30: SK chemicals Recent Developments

Table 31: Meda Pharmaceuticals Inc. Products Offered

Table 32: Meda Pharmaceuticals Inc. Recent Developments

Table 33: Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered

Table 34: Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments

Table 35: Apricus Biosciences, Inc. Products Offered

Table 36: Apricus Biosciences, Inc. Recent Developments

Table 37: Teva Pharmaceutical Industries Ltd. Products Offered

List of Figures

Figure 01: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, 2020–2028

Figure 02: Market Value Share, by Drug Class (2020)

Figure 03: Market Value Share, by Distribution Channel (2020)

Figure 04: Market Value Share, by Region (2020)

Figure 05: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

Figure 06: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Viagra, 2020–2028

Figure 07: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Cialis, 2020–2028

Figure 08: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Staxyn/Levitra, 2020–2028

Figure 09: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Stendra/Spedra, 2020–2028

Figure 10: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by others, 2020–2028

Figure 11: Global Erectile Dysfunction (ED) Drug Market Value Share Analysis, by Distribution channel, 2020 and 2028

Figure 12: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2020–2028

Figure 13: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2020–2028

Figure 14: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2020-2028

Figure 15: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Region, 2020 and 2028

Figure 16: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2028

Figure 17: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country, 2020 and 2028

Figure 18: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

Figure 19: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 20: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2028

Figure 21: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 22: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

Figure 23: Europe Erectile Dysfunction (ED) Drugs Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 24: Asia Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2028

Figure 25: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 26: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2020 and 2028

Figure 27: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 28: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2028

Figure 29: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 30: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2020 and 2028

Figure 31: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 32: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2028

Figure 33: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 34: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

Figure 35: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 36: Global Erectile Dysfunction (ED) Drugs Market Share Analysis, by Company (2020)

Figure 37: Pfizer, Inc. Breakdown of Net Sales, by Region, 2020

Figure 38: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2018–2020

Figure 39: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018–2028

Figure 40: Dong-A ST Co., Ltd. Breakdown of Net Sales, by Businesses Segment

Figure 41: Dong-A ST Co., Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2018–2020

Figure 42: Dong-A ST Co., Ltd. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018–2028

Figure 43: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2018–2020

Figure 44: Eli Lilly and Company R&D Intensity and Sales & Marketing Intensity – Company Level, 2018–2028

Figure 45: Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2020

Figure 46: Eli Lilly and Company Breakdown of Net Sales, (by Endocrinology Level), 2020

Figure 47: Bayer AG Breakdown of Net Sales, by Region, 2020

Figure 48: Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 49: Bayer AG R&D Intensity and Net Income (US$ Mn) – Company Level, 2020

Figure 50: VIVUS, INC. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018–2028

Figure 51: VIVUS, INC. Breakdown of Revenue, by Operation (Company Level), 2020

Figure 52: VIVUS, INC. Breakdown of Research and Development Expenses, 2020

Figure 53: SK chemicals Consolidated Balance Sheet (US$ Bn), 2020

Figure 54: SK chemicals Revenue (US$ Bn) and Y-o-Y Growth (%), 2018–2020

Figure 55: SK chemicals R&D Intensity and Net Income (US$ Mn) – Company Level, 2018–2020

Figure 56: Meda Pharmaceuticals Inc. Breakdown of Net Sales, by Region, 2020

Figure 57: Meda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020

Figure 58: Meda Pharmaceuticals Inc. Selling, Medicine &business development and administrative expenses (US$ Mn) – Company Level, 2018-2020

Figure 59: Apricus Biosciences, Inc. Breakdown of Net Sales, by Region, 2020

Figure 60: Apricus Biosciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 61: Apricus Biosciences, Inc. R&D and General & administrative (US$ Mn) – Company Level, 2018–2028

Figure 62: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2018–2020

Figure 63: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2018–2028

Figure 64: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2020

Figure 65: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2020

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Erectile Dysfunction (ED) Drugs Market